SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1520)5/14/2003 12:11:48 PM
From: nigel bates  Respond to of 3044
 
The trials will be large and expensive

And hopefully paid for by some pharma.



To: scaram(o)uche who wrote (1520)5/14/2003 12:17:17 PM
From: Ian@SI  Read Replies (1) | Respond to of 3044
 
modest efficacy with pronounced toxicity.

In the conference call this morning, I believe it was stated that MLNM expected fewer and less severe side effects in patients getting earlier treatment with V than was the case in the PhII trials.

I interpreted this as being less toxic than may currently be feared.

What causes you to expect pronounced toxicity from V when treating solid tumours?

Thanks,
Ian


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News